Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Klarna preparing to revive NY public listing - report

(Sharecast News) - Buy now, pay later (BNPL) firm Klarna is reportedly preparing to revive a public listing in New York this autumn, months after being forced to abort a previous attempt amid tariff-induced market turmoil. According to Sky News, Klarna and its advisers are aiming to launch an initial public offering in September or October if market conditions are conducive.

Sky said the timing of the IPO is being continuously reviewed, according to insiders, but is likely to take place well before the end of the year.

In a memo sent to investors this month and seen by Sky, Klarna finance chief Niclas Neglen said: "Our momentum continues to build, and our intention to list remains firm.

"We're closely monitoring market conditions and will move swiftly when the timing aligns."

He added that shareholders should expect to be notified 48 hours in advance of an IPO being launched.

The company has been attempting to shed its label as a BNPL-focused company and reposition itself as a digital bank in recent months.

This week, it said it had been authorised by the City watchdog as an Electronic Money Institution (EMI), allowing it to begin offering cashback to its 11m UK customers later this year.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.